Skip to main content

Advertisement

SpringerLink
Log in

BRAF mutation predicts resistance to anti-EGFR monoclonal antibodies in wild-type KRAS metastatic colorectal cancer

  • Letter to the Editor
  • Published:
Journal of Cancer Research and Clinical Oncology Aims and scope Submit manuscript

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

References

  • Di Nicolantonio F, Martini M, Molinari F et al (2008) Wild-type BRAF is required for response to panitumumab or cetuximab in metastatic colorectal cancer. J Clin Oncol 26:5705–5712

    Article  PubMed  Google Scholar 

  • Laurent-Puig P, Cayre A, Manceau G et al (2009) Analysis of PTEN, BRAF, and EGFR status in determining benefit from cetuximab therapy in wild-type KRAS metastatic colon cancer. J Clin Oncol 27:5924–5930

    Article  CAS  PubMed  Google Scholar 

  • Loupakis F, Ruzzo A, Cremolini C et al (2009) KRAS codon 61, 146 and BRAF mutations predict resistance to cetuximab plus irinotecan in KRAS codon 12 and 13 wild-type metastatic colorectal cancer. Br J Cancer 101:715–721

    Article  CAS  PubMed  Google Scholar 

  • Sartore-Bianchi A, Di Nicolantonio F, Nichelatti M et al (2009) Multi-determinants analysis of molecular alterations for predicting clinical benefit to EGFR-targeted monoclonal antibodies in colorectal cancer. PLoS One 4:e7287

    Article  PubMed  Google Scholar 

Download references

Conflict of interest statement

We declare that we have no conflict of interest.

Author information

Authors and Affiliations

  1. Department of Epidemiology, School of Public Health and Tropical Medicine, Southern Medical University, Guangzhou, China

    Chen Mao, Ru-Yan Liao & Qing Chen

Authors
  1. Chen Mao
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Ru-Yan Liao
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Qing Chen
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Qing Chen.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Mao, C., Liao, RY. & Chen, Q. BRAF mutation predicts resistance to anti-EGFR monoclonal antibodies in wild-type KRAS metastatic colorectal cancer. J Cancer Res Clin Oncol 136, 1293–1294 (2010). https://doi.org/10.1007/s00432-010-0922-8

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00432-010-0922-8

Keywords

Search

Navigation